Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025 - 2026)

Oramed Pharmaceuticals filings provide 1 years of Non-Current Deferred Tax Liability readings, the most recent being $7.9 million for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability changed N/A to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.9 million for FY2025, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability hit $7.9 million in Q4 2025 for Oramed Pharmaceuticals, roughly flat from $7.9 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $7.9 million in Q3 2025 and bottomed at $7.9 million in Q4 2025.